Development of bullous pemphigoid during nivolumab therapy

JAAD Case Reports

Volumn 2, Issue 6, 2016, Pages 442-444

  Damsky, William ^a   Kole, Lauren ^a   Tomayko, Mary M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bullous pemphigoid; nivolumab; pembrolizumab; programmed cell death protein 1; programmed cell death protein 1 inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; CLOBETASOL; CLONAZEPAM; COMPLEMENT COMPONENT C3; CORTICOSTEROID; DESVENLAFAXINE; FUROSEMIDE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; LEVOTHYROXINE; METOCLOPRAMIDE; MORPHINE; NIVOLUMAB; OMALIZUMAB; PANTOPRAZOLE; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; ROSUVASTATIN; STEROID;

AGED; ANTIBODY BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARM INJURY; ARTICLE; BACK; BLISTER; BLOOD CELL COUNT; BULLOUS PEMPHIGOID; BUTTOCK; CANCER STAGING; CANCER THERAPY; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEPRESSION; DERMOEPIDERMAL JUNCTION; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EOSINOPHIL COUNT; EROSION; FEMALE; HAND INJURY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOTHYROIDISM; IMMUNOFLUORESCENCE; INFLAMMATORY INFILTRATE; LUNG ADENOCARCINOMA; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MUCOSA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIASIS; RASH; SCORING SYSTEM; THIGH; VESICULAR RASH;

EID: 85002170660     PISSN: None     EISSN: 23525126     Source Type: Journal    
DOI: 10.1016/j.jdcr.2016.05.009     Document Type: Article

References (10)

1. 1 Yu, K.K., Crew, A.B., Messingham, K.A., Fairley, J.A., Woodley, D.T., Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol 71 (2014), 468–474.
2. 2 Hwang, S.J., Carlos, G., Wakade, D., et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. J Am Acad Dermatol 74 (2016), 455–461.e1.
3. 3 Hwang, S.J., Carlos, G., Chou, S., Wakade, D., Carlino, M.S., Fernandez-Penas, P., Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Res 26 (2016), 413–416.
4. 4 Naidoo, J., Schindler, K., Querfeld, C., et al. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer Immunol Res 4 (2016), 383–389.
5. 5 Xia, Y., Jeffrey Medeiros, L., Young, K.H., Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim Biophys Acta 1865 (2016), 58–71.
6. 6 Colliou, N., Picard, D., Caillot, F., et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med, 5, 2013, 175ra30.
7. 7 Mauri, C., Menon, M., The expanding family of regulatory B cells. Int Immunol 27 (2015), 479–486.
8. 8 Li, Q., Liu, Z., Dang, E., et al. Follicular helper T Cells (Tfh) and IL-21 involvement in the pathogenesis of bullous pemphigoid. PLoS One, 8, 2013, e68145.
9. 9 Antiga, E., Quaglino, P., Volpi, W., et al. Regulatory T cells in skin lesions and blood of patients with bullous pemphigoid. J Eur Acad Dermatol Venereol 28 (2014), 222–230.
10. 10 Voskens, C.J., Goldinger, S.M., Loquai, C., et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One, 8, 2013, e53745.